newsfilter
← Latest News
GlobeNewswire·

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease

BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first patient in UPSTREAM